Company profilePharmaceutical#799 of 1,318 in Pakistan2 DRAP alerts

BF BIOSCIENCE LTD

Pharmaceutical company · 10 brands · 24 molecules

Ranked #31 of 44 companies in Antineoplastics

10 registered products 12 pharmaceutical brands 24 distinct molecules 2 DRAP alerts

Company overview

10
registered products
12
pharmaceutical brands
24
distinct molecules
4
therapeutic classes
2
DRAP alerts

BF BIOSCIENCE LTD is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 10 product registrations across 24 distinct molecules. Its portfolio is concentrated in Antineoplastics and Cancer. DRAP has issued 2 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by BF

4 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

4
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
20264

Top molecules by brand count

Doxorubicinhcl.................50Mg1 brand
Filgrastim ...... 300 Mcg1 brand
Filgrastim1 brand
Peginterferon Alfa-2A1 brand
Paclitaxel ...... 30 Mg1 brand
Paclitaxel1 brand
Paclitaxel ...... 100 Mg1 brand
Paclitaxel ...... 150 Mg1 brand
Paclitaxel ...... 300 Mg1 brand
Insulin1 brand

Therapeutic classes

Antineoplastics · 2Cancer · 1Immunostimulants · 1Other Antianemic Preparations (Erythropoietin Products) · 1

Conditions treated

Oncology · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official17 products · Rs 814.56 – Rs 41,620.43
DVAGO1 products · Rs 3,705 – Rs 3,705
Servaid1 products · Rs 2,250 – Rs 2,250
Median across source: Rs 3,705

Regulatory record

2 alerts in the DRAP feed we track.

Recall Alert: Drug Product; Kempol 120ml/5mL Pediatric Syrup by M/s Alkemy Pharmaceutical
2022-12-01
Drug Product Recall: Lefin Pediatric Suspension (Batch # 332v) by M/s. Leama Chemi Pharma
2021-11-12

Competitive set

Companies whose registered portfolio overlaps most with this one.

Get the full profile for BF

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.